{"filing":{"accession_number":"0001213900-26-097856","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-06-30","primary_document":"ea0304367-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026097856/ea0304367-6k_canfite.htm"},"events":[{"id":31832,"run_id":29231,"accession_number":"0001213900-26-097856","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release dated September 8, 2026, announcing Can-Fite's Q2 2026 (H1 2026) financial results and clinical progress. The exhibit discloses six-month revenues ($0.20M), R\u0026D expenses ($3.45M), G\u0026A expenses ($1.42M), net loss ($4.60M), and cash position ($7.03M), along with condensed consolidated balance sheets and statements of operations. While the release emphasizes clinical milestones (longer-than-anticipated overall survival in the Phase III HCC study, pancreatic cancer Phase 2a results, and psoriasis Phase 3 interim analysis stage), the core disclosure is the periodic financial results for the first half of 2026, making this an earnings release. The clinical updates are material context for investors assessing the company's pipeline value and cash burn trajectory.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":34844,"accession_number":"0001213900-26-097856","item_number":"EX-99.3","item_title":"ea030436701ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release dated September 8, 2026, announcing Can-Fite's Q2 2026 (H1 2026) financial results and clinical progress. The exhibit discloses six-month revenues ($0.20M), R\u0026D expenses ($3.45M), G\u0026A expenses ($1.42M), net loss ($4.60M), and cash position ($7.03M), along with condensed consolidated balance sheets and statements of operations. While the release emphasizes clinical milestones (longer-than-anticipated overall survival in the Phase III HCC study, pancreatic cancer Phase 2a results, and psoriasis Phase 3 interim analysis stage), the core disclosure is the periodic financial results for the first half of 2026, making this an earnings release. The clinical updates are material context for investors assessing the company's pipeline value and cash burn trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:23:46.887661+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34842,"accession_number":"0001213900-26-097856","item_number":"EX-99.1","item_title":"ea030436701ex99-1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.92,"reasoning":"This exhibit is an \"Operating and Financial Review and Prospects\" section for the six-month period ended June 30, 2026, accompanying a Form 6-K filing. It presents interim financial statements, cash flow data, and management's discussion of operations for the first half of 2026. This is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings press release. The document explicitly states it should be read \"in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K,\" confirming it is part of a periodic filing rather than an event disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:23:46.887661+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-08"},{"id":34843,"accession_number":"0001213900-26-097856","item_number":"EX-99.2","item_title":"ea030436701ex99-2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a condensed consolidated interim financial report for Can-Fite BioPharma Ltd. as of and for the six months ended June 30, 2026. The document explicitly states \"UNAUDITED\" and presents balance sheets, statements of operating loss, changes in equity, and cash flows for the interim period. Critically, Note 1(b) discloses substantial doubt about the company's ability to continue as a going concern—a material disclosure that would affect a reasonable investor's assessment. The company reports a net loss of $4.6 million for the six-month period, negative operating cash flows of $5.3 million, and declining cash balances ($2.985 million at June 30, 2026 vs. $5.528 million at December 31, 2025), with reliance on future financing to execute R\u0026D plans.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:23:46.887661+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-08"},{"id":34844,"accession_number":"0001213900-26-097856","item_number":"EX-99.3","item_title":"ea030436701ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release dated September 8, 2026, announcing Can-Fite's Q2 2026 (H1 2026) financial results and clinical progress. The exhibit discloses six-month revenues ($0.20M), R\u0026D expenses ($3.45M), G\u0026A expenses ($1.42M), net loss ($4.60M), and cash position ($7.03M), along with condensed consolidated balance sheets and statements of operations. While the release emphasizes clinical milestones (longer-than-anticipated overall survival in the Phase III HCC study, pancreatic cancer Phase 2a results, and psoriasis Phase 3 interim analysis stage), the core disclosure is the periodic financial results for the first half of 2026, making this an earnings release. The clinical updates are material context for investors assessing the company's pipeline value and cash burn trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:23:46.887661+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-08"}]}